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Multiple recent investigations have highlighted the promise of helminth-based
therapies for the treatment of inflammatory disorders of the intestinal tract
of humans, including inflammatory bowel disease and coeliac disease.
However, the mechanisms by which helminths regulate immune responses,
leading to the amelioration of symptoms of chronic inflammation are unknown.
Given the pivotal roles of the intestinal microbiota in the pathogenesis of these
disorders, it has been hypothesized that helminth-inducedmodifications of the
gut commensal floramaybe responsible for the therapeutic properties of gastro-
intestinal parasites. In this article,we review recent progress in the elucidationof
host–parasite–microbiota interactions inboth animalmodels of chronic inflam-
mation and humans, and provide a working hypothesis of the role of the gut
microbiota in helminth-induced suppression of inflammation.1. Introduction
The human gastrointestinal tract is inhabited byapproximately 1013–1014 bacterial
cells, which together are known as the gut microbiota. This complex network of
commensal microorganisms exerts a number of specialized functions beneficial
to the host, including absorption of nutrients, synthesis of essential organic com-
pounds, protection against pathogens and contribution to the development of the
intestinal immune system [1,2]. Perturbations of the gutmicrobial ecology (¼ ‘dys-
biosis’) have been implicated in a number of diseases, including obesity,
malnutrition, type I and type II diabetes, cancer and neurological disorders
[1,3]. In addition, intestinal dysbiosis is associated with a range of chronic inflam-
matory disorders of the gastrointestinal tract, including Crohn’s disease (CD),
ulcerative colitis (UC) [4] and coeliac disease (CeD) [5]. These diseases exact an
enormous toll in developed countries, with CD and UC being the two most
common forms of inflammatory bowel disease (IBD), estimated to cost the
economy of the United Kingdom alone approximately £1 billion per year [6].
CD and UC are lifelong inflammatory conditions of the colon and small intes-
tine, characterized by aberrant responses of the mucosal immune system against
the commensal flora [7]. While genetic factors contribute to the susceptibility to
IBD [7], a number of studies support a pivotal role for environmental factors
such as the gut microbiota in the pathogenesis of these chronic conditions [8].
IBD is associated with alterations in the nature of the microbial communities
within the gut, which may affect immune development and intestinal barrier
function. As a result, the breakdown in tolerance and compartmentalization of
commensal microorganisms then perpetuates disease by stimulating the acti-
vation of inflammatory T cells, resulting in chronic inflammation [8]. While the
exact mechanisms which determine this cascade of biological events are yet to
be fully determined, a high concentration of mucosally-associated bacteria,
together with the presence of enteric bacterial pathogens (e.g. adherent/invasive
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Figure 1. Potential role for microbiota in helminth-mediated suppression of autoimmune diseases? Helminths, including Trichuris sp. and hookworms are thought to
limit the severity of IBDs and autoimmune diseases via promotion of type 2 and regulatory T cell responses that counteract pro-inflammatory type 1 or type 17
immune responses. However, emerging evidence suggests that helminth-mediated immune modulation may be, in part, due to alterations in the composition of the
intestinal microbiota, which can profoundly influence immune cell development and function in the intestine. ES, excretory/secretory. (Online version in colour.)
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factors contributing to intestinal dysbiosis (e.g. impaired bac-
terial killing) have been hypothesized to contribute to the
development and severity of disease [8].
A role for intestinal dysbiosis in the pathogenesis and
severity of CeD has been recently hypothesized [5,9]. CeD is
an autoimmune disorder caused by an inappropriate response
to dietary gluten, where symptoms include intestinal pain and
discomfort, chronic constipation or diarrhoea, impaired nutri-
ent absorption, anaemia and fatigue [10]. In people with CeD,
ingestion of even trace amounts of gluten (10–50 mg), a major
component of foods containing wheat, barley and rye, can
cause infiltration of pro-inflammatory T cells to the small intes-
tine, which causes apoptosis in the epithelial cells that form
the intestinal barrier [11]. This inflammation is compounded
by the production of autoantibodies against enzymes that pro-
cess gluten, which are deposited in the intestine and promote
truncation of the villi lining and destruction of the epithelial
barrier [12]. An expansion in populations of Bacteroides spp.,
together with a reduction of Bifidobacterium spp., has been
associated with the development of CeD [13]. Interestingly,
adherence to a strict gluten-free diet (GFD) does not result
in restoration of microbial balance, thus leading to the hypo-
thesis of a link between genotype and intestinal dysbiosis
that may predispose to disease [9]. To date, there are no effec-
tive cures for IBD or CeD that will enable affected individuals
to engage in normal diets and lead symptom-free lives;
however, modulation of the gut microbiota via the use of pre-
biotics, probiotics, antibiotics or faecal transplants could be
viable therapeutic strategies.2. Helminth-therapy to treat inflammatory gut
disorders
One theory for the increased incidence of allergic and auto-
immune diseases in the developed world, including IBD and
CeD, is that improved sanitation has reduced our exposure to
pathogens in childhood, which affects the development of the
immune system. Consequently, there are increases in the inci-
dence of immune disorders related to inappropriate responses
to harmless stimuli—commonly referred to as the ‘hygiene
hypothesis’ [14]. Therefore, in recent years, there have been
multiple attempts to exploit the hygiene hypothesis via the
controlled re-introduction of infectious agents with immuno-
suppressive properties, such as parasitic helminths [15–18].In particular, two gastrointestinal parasitic nematodes,
namely whipworms (Trichuris sp.) and hookworms (Necator
americanus), have been investigated in a range of studies in
both humans and animal models aimed at developing novel
treatment strategies against IBD and CeD, respectively [16,19].
As a consequence of these pilot studies, there have been
intriguing observations that some of the immunoregulatory
capacity ofwormsmay be directly or indirectly related to altera-
tions in intestinal microbial communities (figure 1), which will
be the focus of the remainder of this article.3. Therapeutic potential of helminths and the
role of the gut microbiota
(a) Whipworms
Whipworms of the genus Trichuris are parasites of the
large intestine of mammals. Infection occurs following
the ingestion of the embryonated eggs, which hatch in the
small intestine and release the infective larvae that develop
to adults within the large intestine, partially embedding
themselves within the epithelial lining [20,21]. Interestingly,
the presence of commensal bacteria within the host is essen-
tial for the hatching of Trichuris eggs and hence the successful
establishment of Trichuris infection [22]. Indeed, using individ-
ual in vitro cultures of five strains of bacteria (including E. coli,
an extremely commongut commensal) and one of yeast, Hayes
et al. [22] observed successful hatching of embryonated eggs of
the murine whipworm, T. muris, similarly to that induced by
incubation of eggs with tissue explants of mouse caecum con-
taining the commensal microflora. Removal of bacterial or
yeast cells from cultures prevented hatching, thus revealing,
for the first time, a close association between a metazoan para-
site and the gut microbiota [22]. Like many other species of
intestinal helminths, Trichuris infection elicits a biased type 2
immune response in its host, which is thought to be involved
in downregulating type 1 and type 17 immune responses that
are typically associated with many autoimmune diseases
including IBD [16].
Of the approximate 70 known Trichuris species, T. trichiura
and T. suis are known as the human and porcine whipworms,
respectively. However, the latter can establish asymptomatic,
transient infections in the large intestine of humans [23],
thus providing scope for investigations into the role of this
parasite as a safe alternative therapeutic strategy for allergic
and autoimmune disorders [23]. Indeed, in recent years,
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of CD and UC in patients subjected to oral administration of
T. suis ova (TSO) [16,24–26]. In addition, ingestion of TSO by
volunteers affected by multiple sclerosis was followed by a
reduction in number of brain lesions (as verified by magnetic
resonance imaging), thus providing evidence for the systemic
nature of the immune response elicited by this parasite [27].
Efforts to elucidate the mechanisms by which experimen-
tal whipworm infections lead to improvement of clinical
symptoms of immune-mediated diseases have primarily
focused on the immunoregulatory properties of parasites
[16]. For instance, a number of studies using mouse models
of IBD and helminth infections [28] have demonstrated that
elements of both the innate and adaptive immune systems
are modulated by helminths. These include suppression of
interferon (IFN)g and interleukin (IL)-17 expression, increased
type 2 cytokine responses, induction of regulatory T cell
responses and cytokines such as IL-10, transforming growth
factor (TGF)-beta and IL-22 and the recruitment of alternatively
activated macrophages, dendritic cells and B cells [28,29].
However, the exact mechanisms by which administration of
TSO results in improvement of clinical indices of inflammation
in human patients affected by IBD remain to be elucidated.
Importantly, while regulation of the host immune system by
helminths such as TSO is one of the likely mechanisms by
which the parasites can suppress IBD symptoms, whether
these effects are direct (via the excretion of immunomodulatory
parasite proteins) or indirect, for example via alterations in the
nature of intestinal environment (e.g. the microbiota) remains
to be defined.
Given the pivotal roles that disturbances in the intestinal
microbiota play in multiple immune disorders [1], and
the fact that gastrointestinal parasites and the commensal
flora share the same environmental niche [30], there is an
increasing interest in understanding helminth–microbiota
interactions and their relative contributions to health and dis-
ease. For instance, studies involving experimental infections
with Heligmosomoides polygyrus bakeri in a mouse model of
IBD revealed a significant expansion of the bacterial family
Lactobacillaceae in the ileum of infected mice, which corre-
lated with improved disease outcome [31,32]. Similarly, the
administration of a single dose of TSO was able to alter the
composition of the gut microbiota of infected pigs, including
a reduction in the abundance of Fibrobacter and Ruminococcus
and an expansion of Campylobacter [33]. In addition, a study
using a primate model of idiopathic chronic diarrhoea (ICD)
has demonstrated that the therapeutic ability of T. trichiura
whipworms to improve clinical symptoms of inflammation
was associated with significant changes in the composition
and relative abundance of different gut bacterial species [34].
In particular, a marked reduction in the bacterial phylum
Cyanobacteria was observed following Trichuris adminis-
tration to macaques with ICD when compared with healthy
controls, accompanied by an expansion of Bacteroidetes and
Tenericutes; in addition, bacterial diversity was increased in
Trichuris-infected ICD macaques [34]. The authors attributed
these changes to the restoration of a ‘healthy’ flora driven by
the parasite [34]. Notably, bacterial attachment (one of the
key factors contributing to the pathogenesis of IBD) was
substantially reduced following Trichuris treatment, thus
suggesting a role for the parasite in mucosal healing which,
in turn, results in a reduction of bacteria-mediated immune-
stimulation [34,35]. Each of these studies investigating therelationships between helminth parasites and the commensal
flora in animal models of inflammation have shed at least
some light on the potential roles of the gut microbiota in
whipworm-mediated suppression of inflammation [36]. How-
ever, in order to establish whether similar mechanisms occur
during helminth infections in humans, studies of the impact
of parasite colonization on the composition of the human gut
microbiota are necessary.(b) Hookworms
Hookworms, including Ancylostoma duodenale and
N. americanus, are blood-feeding nematodes that inhabit the
small intestine of humans [18]. Necator americanus is the most
widely distributed human hookworm, causing significant mor-
bidity for the infected host when worm burdens become high
and/or diet is inadequate [37]. The infection occurs when the
infective third-stage larvae (L3s) penetrate the skin of a suscep-
tible human host after cuticular shedding [38]; subsequently,
larvae enter the subcutaneous tissue and migrate to the small
intestine, via the circulatory system, to the heart and lungs,
where they moult to fourth stage larvae (L4s). From the lungs,
the larvae migrate (via the trachea and pharynx) to the small
intestine, where they develop to adult males and females [38].
The larvaemature to adult stages and attach by their buccal cap-
sule to the intestinal mucosa where their voracious appetite for
blood results in iron-deficiencyanaemia, themajor pathogenesis
associated with hookworm infection.
While heavy burdens of hookworm parasites are associ-
ated with pathological effects, experimental infections with
small numbers of N. americanus are safe and well tolerated
[39–42]. In addition, the chronic nature of hookworm infec-
tions presents advantages for helminth-based therapy when
compared with administration of T. suis—as the parasite is
adapted to long-term survival in humans it need not be
continuously administered. In modern sanitary environments,
hookworm-infected individuals pose no risk of transmission
to others [15]. The immune response to hookworm infection
is similar to that of other intestinal helminths (including
whipworms), with increased expression of the regulatory cyto-
kines IL-10 and TGFb, expansion of Foxp3þ regulatory T cells,
increased IL-22 and IL-5 expression, and reductions in IL-23,
IFNg and IL-17A levels [42–44]. In addition, when adminis-
tered to mouse models of IBD, hookworm excretory/
secretory products protect against inflammation and weight
loss [45], thus providing support to further investigations of
hookworm-based therapies for the treatment of chronic gut
inflammatory diseases of humans. Indeed, experimental
N. americanus infections have been shown to confer temporary
benefit to patients with active CD [46], and improve gluten
tolerance in CeD volunteers [43]. However, similarly
to Trichuris-based therapies, the elucidation of the exact
mechanisms by which these parasites are able to suppress
the symptoms of chronic inflammation is pivotal to the
transfer of hookworm-based therapies from the laboratory to
the clinic.
Recently, our laboratory conducted a pilot study to explore
the impact of experimental infections withN. americanus on the
human gutmicrobiota [47]. Eight volunteers were infectedwith
N. americanus larvae while on GFD, and the changes in relative
abundance of individual bacterial species within the faeces
were analysed [47]. Following massively parallel sequencing
of two distinct hypervariable regions of the bacterial 16S
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Principal Coordinates Analysis revealed strong clustering of
the samples by individual, rather than by infection status,
thus indicating that the community composition of each subject
remained stable over time [47]. Interestingly, an increase in the
number of observed bacterial species (¼ richness) was observed
eight weeks post-infection; however, this difference was just
below the statistical significance level when corrected for
multiple testing [47]. Further investigations are currently under-
wayexamining the changes in commensal bacterial communities
at later time points and following gluten challenges.
This observation of increased bacterial richness supports
the results from a recent study [48] showing that human
infections by gastrointestinal helminths (including Trichuris,
hookworms and the intestinal roundworm Ascaris sp.) in
endemic areas are associated with an increase in richness and
diversity of the gut microbiota. Intriguingly, a higher species
richness of the gut microbiota has been associated with ‘heal-
thier’ intestinal homeostasis [49–51]. For example, a study
comparing the intestinal microbiota of subjects suffering
from IBD with that of healthy controls revealed that species
richness was significantly higher in the latter [49]; in addi-
tion, the microbiota isolated from ‘histologically normal’,
non-inflamed tissue from diseased subjects displayed a signifi-
cantly increased species richness when compared with that
from inflamed (as assessed by histological examination)
biopsy samples from the same individuals [49]. Therefore,
based on the results of our and others’ investigations linking
an increase inmicrobial species richness to (i) human infections
by gastrointestinal parasites [47,48] and (ii) the absence or ame-
lioration of clinical and histological indices of inflammation
[34,49–51], it is tempting to speculate that the therapeutic prop-
erties of hookworms and other helminths are partly associated
with their ability to promote species richness and restore/
maintain microbial (and immune) homeostasis in the gastroin-
testinal tract [47]. Clearly, in order to address this hypothesis in
greater detail, larger human trials in a variety of inflammatory
disease settings are required, where both faecal andmucosally-
associated bacterial communities at the sites of inflammation
are examined.4. Concluding remarks
The complex relationships between the human host and the
commensal gut microbiota have been hypothesized to result
from a lengthy process of coevolution, whereby the host
benefits from the metabolic functions of the gut microbeswhile providing them with a protective environment [52].
Gastrointestinal parasitic helminths have also evolved numer-
ous strategies to survive and reproduce within the body of the
host [53]; therefore, it is conceivable that, in a dysbiotic
environment, parasites may actively (directly or indirectly)
contribute to reinstating the gut homeostasis via modulating
the composition of the gut microbiota. Indeed, over the last
few years, a body of evidence has been generated that links
infections by gastrointestinal parasitic helminths with quanti-
tative and qualitative modifications of the gut microbiota, in
both animals and humans, and under both natural and exper-
imental settings [31,34,47,48,53,54]. However, the nature of the
parasite–microbiota interactions that underpin such modifi-
cations is yet to be elucidated. In a recent study, Reynolds
et al. [32] hypothesized that changes in the composition of
the gut microbiota of mice infected with H. polygyrus may be
a consequence of: (i) the secretion of antimicrobial components
by the parasite that actively modify the microbiota, (ii) the
disruption of the epithelial barrier by the parasite that alters
the intestinal environment and favours the establishment of
selected commensals, or (iii) the stimulation of specific
immune responses (such as expansion of Tregs) that actively
contribute to a shift in gut microbiota [32]. Whether parasite-
associated changes in gut microbiota are a direct consequence
of the infection or, rather, the immune response elicited by hel-
minths remains to be determined. In the future, mechanistic
studies, in both normal and germ-free mice, focusing on the
effects of experimental infectionswithgastrointestinal helminths
on both the gut microbiota and host responseswill facilitate elu-
cidation of this intriguing conundrum. For instance, studies of
global gene expression changes occurring at the site of parasite
attachment (and, for instance, in response to the administration
of an inflammatory stimulus) may provide a better understand-
ing of the relationships between the parasite, the host responses
and the ecologyof the gutmicrobiota andmay, in turn, assist the
development of novel, helminth-based therapeutics of chronic
inflammatory gut disorders.
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